Ilya Rachman, MD PhD
lya Rachman is the Chief Executive Officer of Immix Biopharma, Inc. Dr. Rachman is a physician/scientist and former clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson.
Ilya founded a Clinical Research organization that conducted clinical trials of pharmaceutical drugs, and completed several clinical trials as a Principal Investigator building strong relationships in the clinical research industry.
Gabriel Morris,, BA
Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC, a life sciences advisory and investment firm based in San Francisco, since founding. Prior, Mr. Morris was the interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company, where he completed a growth […]
Michael Grabow
Michael is the Chief Commercial Officer of Immix Biopharma, Inc. Michael has more than 25 years of biopharmaceutical commercialization experience. Prior to joining Immix, Michael was Head of Commercial Operations at Chimerix, Inc., where he led Go-To-Market Strategy and Launch of orphan drug MODEYSO® (dordaviprone), a first-in-disease therapy that was granted accelerated approval in 2025 […]
Richard Graydon, MD, PhD
Content to follow.
Mel Davis-Pickett
Mel Davis-Pickett is the Head of CMC Technical Development at Immix Biopharma, Inc. Mel possesses more than 16 years of experience in cell therapy analytical development at Bristol Myers Squibb (BMS), and the Fred Hutchison Institute. At BMS, Mel led analytical development activities for three CAR T programs, including Breyanzi®, from early phase through BLA; […]
Denise Bruns, PHD
